A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
Study sponsor: Spruce Biosciences
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-10-31Actual
Enrollment · participants100Actual
Source updated2025-10-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.